Aurinia Pharmaceuticals earnings were $298.2M for the trailing 12 months ending Mar 31, 2026, with 669% growth year over year. The latest AUPH earnings report on Mar 31, 2026 announced Q1 2026 earnings of $34.4M, down 83.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AUPH reported annual earnings of $287.2M, with 4,893.1% growth.
AUPH past earnings growth
How has AUPH's earnings growth performed historically?
Aurinia Pharmaceuticals Earnings Reports & History FAQ
What were Aurinia Pharmaceuticals's earnings last quarter?
On AUPH's earnings call on Invalid Date, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 2026 earnings per share (EPS) of $0.26, up 52.94% year over year. Total AUPH earnings for the quarter were $34.36 million. In the same quarter last year, Aurinia Pharmaceuticals's earnings per share (EPS) was $0.17.
Is Aurinia Pharmaceuticals profitable or losing money?
As of the last Aurinia Pharmaceuticals earnings report, Aurinia Pharmaceuticals is currently profitable. Aurinia Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $298.21 million, a 648.43% increase year over year.
What was AUPH's earnings growth in the past year?
As of Aurinia Pharmaceuticals's earnings date in Invalid Date, Aurinia Pharmaceuticals's earnings has grown 668.97% year over year. This is 621.87 percentage points higher than the US Biotechnology industry earnings growth rate of 47.1%. AUPH earnings in the past year totalled $298.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.